

# The Crossroads of Healthcare & Growth

**Your Partner for Accelerated Business Transformation** 

## **Investment Criteria**

#### **Industry Focus + Preferred Subsectors**

- Healthcare Providers
- Healthcare Outsourced Services
- Medical Products

#### **Transaction Types**

- Control Positions in Healthcare Businesses
- Partial Recapitalizations or Buyouts

#### **Transaction Size**

- Target platform EBITDA \$5 \$20M
- Target equity investments \$30 \$150M
- Target add-on investments + Cash Flow Positive

#### **Company Characteristics**

- Headquartered in the United States or Canada
- Founder-owned, entrepreneurially-led
- Strong business model, with a history of consistent growth and profitability
- Positive secular growth trends and resilient end market
- Fragmented market landscape
- Strong demand, implying good revenue visibility (recurring or re-occurring)
- Limited regulatory risk

### Who We Are

Sheridan Capital Partners is a Chicago-based lower middle market private equity firm focused exclusively on helping to build exceptional healthcare companies.

2012

Year Founded >50

Years Collective Experience

100+

Platform and Add-on Investments

Since 2012, Sheridan has sought to build enduring value across the lower middle market by providing collaborative, growth-oriented solutions across Healthcare Providers, Healthcare Outsourced Services, and Medical Products.

# Our Approach

We strive to partner with strong management teams to implement a value creation framework and drive profitable growth:

- Support and supplement existing management talent where required
- + Establish the operating model necessary to effectively scale the business
- Identify accretive M&A opportunities provide capital necessary for integration

# **Select Investments**





**Provider Software** Industry & Technology

June 2025 **Investment Date** Add-On Criteria US



**Plastic Surgery &** Industry **Aesthetics** 

**Investment Date** Add-On Criteria

October 2023 US or Canada



**HC Third Party** Industry **Administration** 

Investment Date June 2023 **US or Canada** Add-On Criteria



**Revenue Cycle** Industry Management

**Investment Date** Add-On Criteria **US or Canada** 





**Pharma** Industry Services

November 2022 **Investment Date** Add-On Criteria Global



**Medical Device** Industry Repair

**Investment Date** May 2022 Add-On Criteria Global



**Post Acute** Industry **Consulting & RCM** 

May 2021



Healthcare Industry

**MSP** 



**Investment Date** Add-On Criteria

**Investment Date** 

Add-On Criteria

**US or Canada** 

DAShealth

**Investment Date** February 2021 Add-On Criteria **US or Canada** 



Industry

**IDD Pharmacy** 

December 2019



Industry

Oral Surgery

**Investment Date** Add-On Criteria

May 2019 Central / Eastern US



Ophthalmology & Industry **Optometry** 

Investment Date **April 2019** Add-On Criteria Realized



Industry

**Physical** Therapy

Investment Date Add-On Criteria

August 2018 Southwestern US



SPEND MEND

Industry

**Cost Cycle** 

**Management** 

January 2018



Industry

**Dermatology** 

Add-On Criteria

**US or Canada** Recapitalized in 2022 Investment Date Add-On Criteria

Investment Date

Add-On Criteria

August 2017 Realized



Industry

Investment Date

**Orthodontics** 



Industry

**Sports Nutrition** Distribution



**Investment Date** Add-On Criteria

February 2016 Realized

September 2013

Realized



Industry

Industry

Investment Date

**Orthodontics** 

September 2015



Industry **Biologics** 



**Pharmacy** 

Veterinary

Investment Date December 2012 Add-On Criteria Realized



Alexandra M. Kier

Managing Director, Business Developmentt 312.273.5353 alexandra.kier@sheridancp.com

**Jake Margolis** 

Senior Associate, Business Development 872.810.2656 jake.margolis@sheridancp.com

Riley DeMuth

**Associate, Business Development** 312.273.5353 riley.demuth@sheridancp.com